user

Bisphosphonates affect signaling pathways utilized by teriparatide [rhPTH(1-34)].

被引：0
|
作者：
Sun, Q
Katz, RW
Morris, SA
Bilezikian, JP
机构：
[1] Columbia Univ, Coll Phys & Surg, Div Endocrinol, New York, NY USA
[2] Columbia Univ, Sch Dent & Oral Surg, New York, NY USA
[3] Aventis Pharmaceut, Bridgewater, NJ USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2003年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S230 / S231
页数：2
相关论文
共 50 条
  • [1] Teriparatide (rhPTH(1-34) improves the structural geometry of the hip
    Uusi-Rasi, K
    Beck, TJ
    Oreskovic, TL
    Sato, M
    Boado, CE
    Zanchetta, JR
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S208 - S208
  • [2] Comparative analysis of the cost-effectiveness of teriparatide [RHPTH(1-34)] versus RHPTH(1-84)
    Borgstroem, F.
    Stroem, O.
    Kutahov, A.
    Marin, F.
    Ljunggren, O.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A396 - A396
  • [3] Pharmacokinetics of Teriparatide (rhPTH[1-34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
    Satterwhite, Julie
    Heathman, Michael
    Miller, Paul D.
    Marin, Fernando
    Glass, Emmett V.
    Dobnig, Harald
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2010, 87 (06) : 485 - 492
  • [4] Teriparatide [RHPTH (1-34)] treatment reduces the incidence of back pain in postmenopausal women with osteoporosis
    Krege, JH
    Xie, L
    Genant, HK
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S75 - S75
  • [5] Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
    Cosman, Felicia
    Eriksen, Erik Fink
    Recknor, Chris
    Miller, Paul D.
    Guanabens, Nuria
    Kasperk, Christian
    Papanastasiou, Philemon
    Readie, Aimee
    Rao, Hanumantha
    Gasser, Juerg A.
    Bucci-Rechtweg, Christina
    Boonen, Steven
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (03) : 503 - 511
  • [6] Teriparatide (rhPTH [1-34]) treatment improves the structure of the proximal femur in women with osteoporosis.
    Semanick, LM
    Uusi-Rasi, K
    Zanchetta, JR
    Bogado, CE
    Eriksen, EF
    Sato, M
    Beck, TJ
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S40 - S40
  • [7] Raloxifene improves the skeletal efficacy of teriparatide [RHPTH (1-34), TPTD] at clinically relevant doses
    Sato, M
    Schmidt, A
    Smith, S
    Ma, LY
    [J]. BONE, 2003, 32 (05) : S211 - S212
  • [8] RALOXIFENE SKELETAL EFFECTS ARE IMPROVED WITH WEEKLY TERIPARATIDE [RHPTH (1-34)] IN OSTEOPENIC OVARIACTOMIZED RATS
    Ma, Y. L.
    Schmidt, A.
    Zeng, Q. Q.
    Zhang, Q.
    Jee, W. S.
    Sato, M.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2004, 74 : S83 - S83
  • [9] Teriparatide -: rhPTH(1-34) -: LY-333334 -: Forteo® -: Treatment of osteoporosis -: Parathyroid hormone
    不详
    [J]. DRUGS OF THE FUTURE, 2001, 26 (08) : 824 - 827
  • [10] Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment
    Spanakis, E. K.
    Sellmeyer, D. E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (04) : 1411 - 1414
12345